Moncef Slaoui, Saurabh Saha, and Francesco De Rubertis (File photos)
February 16, 2021 06:30 AM EST
Startups

Francesco De Ru­ber­tis makes his lega­cy play, re­cruit­ing star ex­ecs and rolling up 10 biotech star­tups in­to a $250M gam­ble on cre­at­ing some­thing new in phar­ma

John Carroll

Editor & Founder

A promi­nent ven­ture start­up shop with deep roots in Eu­ro­pean R&D cir­cles is mak­ing a $250 mil­lion wa­ger that it can cre­ate a new kind …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

A service from the Financial Times